A method for controlling the idiosyncratic hepatotoxicity of Polygonum multiflorum
By establishing a rat model of inflammatory stress, screening and detecting the eflavin-8-O-glucoside and trans styrene glycoside in Polygonum multiflorum extract, the liver injury effect was determined, and the problem of frequent liver injury events in Polygonum multiflorum multiflorum was solved. , provides safety and quality control methods and reduces the risk of liver injury.
Patent Information
- Application Number
- CN201910694095.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-07-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-07-29
AI Technical Summary
The liver injury incidents of Polygonum multiflorum are frequent, and the existing technology lacks effective safety and quality control methods. In particular, the mechanisms of emodin-8-O-glucoside and trans styrene glycoside in hepatotoxicity are not yet clear. Traditional processing theory There is a gap with modern experimental research.
By establishing a liver injury model for inflammatory stress rats with endotoxin replication, Polygonum multiflorum extract mainly contains trans styrene glycoside and eflavin-8-O-glucoside, solutions of these compounds were prepared and administered. Experiment, combined with plasma aminotransferase, liver histopathology and inflammatory cytokine detection, determine its liver injury effect and safety limit.
Successfully identified the correlation between emodin-8-O-glucoside and trans styrene glycoside and liver injury of Polygonum multiflorum, providing a reference for safe use of drugs, reducing the risk of liver injury, and providing clinical safety control of Polygonum multiflorum Material basis.
Smart Images

Figure CN112305211B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of medicinal material safety and quality control, and in particular to a safety quality control method for the special hepatotoxicity of Polygonum multiflorum. Background Art
[0002] Polygonum multiflorum is the dried root of Polygonum multiflorum Thunb., a plant of the Polygonaceae family. There are differences in the clinical application of raw Polygonum multiflorum and processed Polygonum multiflorum. Raw Polygonum multiflorum can dry dampness and moisten the intestines and relieve constipation, while processed Polygonum multiflorum can nourish the liver and kidneys, improve the essence and blood, and darken hair. It has a wide range of clinical applications and is not traditionally considered a toxic Chinese medicine. However, in recent years, there have been frequent incidents of liver damage caused by Polygonum multiflorum and its preparations. Cases of liver damage related to Polygonum multiflorum have been reported in my country, South Korea, Japan, the United Kingdom and other countries, and its safety issues have attracted widespread attention at home and abroad. Summary of the invention
[0003] The following is a summary of the subject matter described in detail herein. This summary is not intended to limit the scope of the claims.
[0004] The applicant has previously analyzed clinical cases and found that the liver damage of Polygonum multiflorum has typical idiosyncratic properties, and its idiosyncratic properties may be closely related to the inflammatory activation state of the body, and based on this, an inflammatory stress rat liver damage evaluation model with endotoxin replication has been established. As we all know, Polygonum multiflorum contains a wide variety of compounds, mainly stilbenes, anthraquinones, flavonoids, tannins, etc. It can be seen from the literature that the material basis research on the hepatotoxicity of Polygonum multiflorum has made certain progress, mainly focusing on anthraquinones and stilbenes. The applicant previously screened out the ethyl acetate part of the Polygonum multiflorum extract that produced hepatotoxic effects on the established immune stress rat model through the target component knock-out / knock-in strategy. The part was identified by mass spectrometry as mainly containing trans-stilbene glycosides (TSG) and emodin-8-O-glucoside (EG). Polygonum multiflorum contains emodin, and it is still unknown whether the liver injury effect of emodin glycoside EG is related to emodin, and there is no relevant literature report at present. In addition, the classic processing theory of Polygonum multiflorum "raw use has cold nature, astringent nature, and is toxic; cooked use has warm nature and is non-toxic" and modern experimental studies have shown that processing can eliminate or reduce the hepatotoxicity of Polygonum multiflorum, and the contents of TSG and EG are significantly reduced after processing.
[0005] Based on the above analysis, EG and TSG are likely to be related to the liver damage of Polygonum multiflorum. In view of the large number of reports on the toxicity of anthraquinone components, this application focuses on the liver damage effect of EG, and also evaluates the liver damage of TSG combined with EG. Objectively evaluate the correlation between the two and the idiosyncratic hepatotoxicity of Polygonum multiflorum, and explore their possible safety limits in combination with clinical case analysis, to provide a reference for establishing risk control measures for liver damage of Polygonum multiflorum from a material basis perspective and improving the level of clinical safety of Polygonum multiflorum.
[0006] Specifically, a method for controlling the idiosyncratic hepatotoxicity of Polygonum multiflorum comprises:
[0007] (1) Determination of the dosage of emodin-8-O-glucoside;
[0008] (2) Preparation of rhein-8-O-glucoside solution: Calculate the required amount of rhein-8-O-glucoside according to the dosage of rhein-8-O-glucoside, dissolve it in 0.5% by mass sodium carboxymethyl cellulose solution, and store it at 4° C. for later use;
[0009] Optionally, the method further comprises the step of preparing a trans-stilbene glycoside solution: calculating the required amount of trans-stilbene glycoside according to the dosage of the trans-stilbene glycoside, dissolving the trans-stilbene glycoside by vortexing with a 0.5% mass fraction sodium carboxymethyl cellulose solution, and storing the solution at 4° C. for later use; and
[0010] Preparation of a mixed solution of rhein-8-O-glucoside and trans-stilbene glycoside: Calculate the required amount of rhein-8-O-glucoside and trans-stilbene glycoside according to the dosage of rhein-8-O-glucoside and trans-stilbene glycoside, vortex and dissolve with 0.5% sodium carboxymethyl cellulose solution, and store at 4°C for later use;
[0011] (3) administering the emodin-8-O-glucoside solution to rats:
[0012] administering the emodin-8-O-glucoside solution to rats by oral gavage;
[0013] Optionally, the method further comprises administering the trans-stilbene glycoside solution and a mixed solution of rhamnosine-8-O-glucoside and trans-stilbene glycoside, and collecting plasma and liver specimens;
[0014] (4) Conduct indicator testing;
[0015] (5) SPSS software was used for statistical analysis.
[0016] In the present application, in step (1), the dosage of emodin-8-O-glucoside can be calculated based on the cumulative toxic dosage of Polygonum multiflorum in clinical practice.
[0017] In the present application, the dosage of emodin-8-O-glucoside can be 8 mg / kg-128 mg / kg, preferably 16 mg / kg-64 mg / kg.
[0018] In the present application, the dosage of trans-stilbene glycoside may be 500 mg / kg.
[0019] In the present application, the dosage of emodin-8-O-glucoside can be 16 mg / kg-64 mg / kg, and the dosage of trans-stilbene glycoside can be 500 mg / kg.
[0020] In the present application, preferably, the dosage of emodin-8-O-glucoside may be 64 mg / kg, and the dosage of trans-stilbene glycoside may be 500 mg / kg.
[0021] In the present application, the endotoxin may be bacterial lipopolysaccharide.
[0022] In the present application, sodium pentobarbital may be used to anesthetize rats.
[0023] In the present application, the dosage of endotoxin may be 2.8 mg / kg.
[0024] In the present application, the dosage of emodin-8-O-glucoside can be 64 mg / kg, the dosage of trans-stilbene glycoside can be 500 mg / kg, and the dosage of endotoxin can be 2.8 mg / kg.
[0025] In the present application, the index detection may include plasma transaminase detection, liver tissue pathology detection, liver tissue cell apoptosis detection and plasma inflammatory cytokine detection.
[0026] In the present application, the detection of plasma transaminases may include the detection of alanine aminotransferase and aspartate aminotransferase.
[0027] In the present application, the detection of liver tissue pathology may include collecting rat liver tissue, fixing it with a universal tissue fixative, conventional pathological sectioning, staining with hematoxylin-eosin staining, observing liver tissue pathological changes under an optical microscope and collecting images.
[0028] In the present application, the detection of liver tissue cell apoptosis may include collecting rat liver tissue, fixing it with a universal tissue fixative, performing routine pathological sectioning, fluorescent staining, observing liver cell apoptosis under an optical microscope and collecting images, and calculating the liver cell apoptosis rate.
[0029] In the present application, the detection of plasma inflammatory cytokines may include detecting the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-10 (IL-10).
[0030] In this application, SPSS software was used for statistical analysis, and the experimental data were The measurement data were analyzed by one-way analysis of variance, with a significance level of P < 0.05 or P < 0.01.
[0031] The present application also provides the use of emodin-8-O-glucoside in the preparation of a drug that does not cause idiosyncratic hepatotoxicity, wherein the dosage of emodin-8-O-glucoside that does not cause idiosyncratic hepatotoxicity is 8-mg / kg-32 mg / kg.
[0032] In the present application, the content of rhein-8-O-glucoside may be ≤0.17% based on the total weight of Polygonum multiflorum.
[0033] In the present application, the content of rhein-8-O-glucoside may be 0.04%-0.17% based on the total weight of Polygonum multiflorum.
[0034] The current limit range of quality control ingredients of traditional Chinese medicine is mainly set artificially based on the size distribution of several batches of samples, and lacks the support of pharmacodynamic toxicology tests or clinical trials. For example, among 20 batches of traditional Chinese medicine, 80% of the batch ingredients exceed (or are lower than) 1.0%, and a limit regulation is often formulated that their content must not be less than (or higher than) 1.0%. Due to the lack of support for pharmacodynamic toxicology tests or clinical trials, the limit range of ingredients is actually not related to the safety and effectiveness of traditional Chinese medicine. The content limit of this application is based on the cumulative clinical toxic dose of Polygonum multiflorum and animal experimental data, and is closely related to toxicity.
[0035] The present application also provides a safe content limit of rhein-8-O-glucoside to control the liver damage risk of Polygonum multiflorum.
[0036] In the present application, the safe content limit of rhein-8-O-glucoside may be ≤0.17% based on the total weight of Polygonum multiflorum.
[0037] In the present application, the safe content limit of rhein-8-O-glucoside may be 0.04%-0.17% based on the total weight of Polygonum multiflorum.
[0038] In the present application, in Polygonum multiflorum, the weight ratio of rhein-8-O-glucoside to trans-stilbene glucoside may be 2:125-8:125.
[0039] The present application also provides the use of the emodin-8-O-glucoside and the trans-stilbene glycoside in evaluating hepatotoxicity. In the use, the dosage of emodin-8-O-glucoside can be 8mg / kg-128mg / kg, preferably 16mg / kg-64mg / kg. In the use, the dosage of trans-stilbene glycoside can be 500mg / kg. In the use, the dosage of emodin-8-O-glucoside can be 16mg / kg-64mg / kg, and the dosage of trans-stilbene glycoside can be 500mg / kg, preferably the dosage of emodin-8-O-glucoside can be 64mg / kg, and the dosage of trans-stilbene glycoside can be 500mg / kg.
[0040] Other features and advantages of the present application will be described in the following description, and partly become apparent from the description, or understood by practicing the present application. The purpose and other advantages of the present application can be realized and obtained by the structures specifically pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] The accompanying drawings are used to provide further understanding of the technical solution of the present application and constitute a part of the specification. Together with the embodiments of the present application, they are used to explain the technical solution of the present application and do not constitute a limitation on the technical solution of the present application.
[0042] Figure 1 The effects of different doses of EG on the activities of plasma ALT and AST in rats with lipopolysaccharide (LPS) model were shown (*P<0.05, **P<0.01 vs normal control group; # P<0.05, ## P<0.01vs model group).
[0043] Figure 2 The results show the effect of TSG combined with EG on the activities of plasma ALT and AST in LPS model rats (*P<0.05, **P<0.01vs normal control group; # P<0.05, ## P<0.01 vs LPS model group; ^P<0.05, ^^P<0.01 vs LPS / EG group).
[0044] Figure 3 The results show the changes in liver tissue pathology in LPS model rats after TSG combined with EG administration (HE (hematoxylin-eosin staining, HE staining 200×).
[0045] Figure 4The results show the effect of TSG combined with EG on hepatocyte apoptosis in LPS model rats (*P<0.05, **P<0.01 vs normal control group; #P<0.05, ##P<0.01 vs LPS model group; ^P<0.05, ^^P<0.01 vs LPS / EG group).
[0046] Figure 5 The results show the effect of TSG combined with EG on the levels of inflammatory cytokines in LPS model rats (*P<0.05, **P<0.01vs normal control group; # P<0.05, ## P<0.01 vs LPS model group; ^P<0.05, ^^P<0.01 vs LPS / EG group). DETAILED DESCRIPTION
[0047] In order to make the purpose, technical solution and advantages of the present application more clear, the embodiments of the present application will be described in detail below with reference to the accompanying drawings. It should be noted that the embodiments and features in the embodiments of the present application can be combined with each other arbitrarily without conflict.
[0048] In this article, LPS stands for lipopolysaccharide, which is a component of the cell wall of Gram-negative bacteria. It is released when the bacteria die and dissolve or when the cells are destroyed by artificial methods. It is an important endotoxin. Trace amounts of LPS can cause a mild, non-damaging inflammatory response and will not develop into obvious hepatocellular toxicity; however, with the release of inflammatory factors, the stability of the tissue environment is destroyed, and the liver's sensitivity to drugs is greatly enhanced, showing drug-specific liver injury. The combined use of non-toxic doses of LPS and some drugs can produce a similar clinical idiosyncratic liver injury response.
[0049] Intragastric administration (ig.) is a commonly used method of drug administration in pharmacology and toxicology experiments. The animal is fixed and a gavage is used to inject the drug solution directly into the animal's stomach through the animal's mouth.
[0050] Intravenous injection (iv.) is a commonly used method of drug administration in pharmacology and toxicology experiments. It is usually injected through the tail vein. The animal is fixed and a syringe is used to inject the drug solution directly into the veins on both sides of the mouse's tail.
[0051] Alanine aminotransferase (ALT) and aspartate transaminase (AST) are both indicators of liver function tests in clinical medicine, used to determine whether the liver is damaged.
[0052] Tumor necrosis factor-α (TNF-α), interferon-gamma (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-2 (IL-2), granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-10 (IL-10) are all important inflammatory cytokines. Their levels are directly related to inflammatory diseases and play a vital role in the occurrence and development of liver damage.
[0053] Except for those noted, all the materials used in the following examples are commercially available.
[0054] 1. Materials
[0055] 1. Experimental Animals
[0056] SPF male Sprague-Dawley (SD) rats, weighing 180-200 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd., with a certificate number of SCXK-(Beijing) 2016-0002. They were housed in cages in the Experimental Animal Center of the Fifth Medical Center of the PLA General Hospital, with free access to water and food, and were fed for 7 days before the experiment. The room temperature of the Experimental Animal Center was (25±2)℃, the humidity was 50-70%, the room was kept in a 12-h lighting and dark alternation, and disinfected regularly.
[0057] 2. Drugs and reagents
[0058] Rheum-8-O-β-D-pyranoglucoside (abbreviated as rheum-8-O-glucoside, EG, batch number 18080601, for content determination, calculated as 98%), trans-2,3,5,4′-tetrahydroxystilbene-2-O-β-D-glucoside (abbreviated as trans-stilbene glycoside, TSG, batch number 18061406, for content determination, calculated as 98%) were purchased from Chengdu Pufeide Biotechnology Co., Ltd.; lipopolysaccharide (LPS) (batch number 057M4013V, 10 0mg / tube) was purchased from Sigma-Aldrich, USA; sodium pentobarbital (batch number 57-33-0) was purchased from Sigma, USA; universal tissue fixative (batch number 174627) was purchased from Wuhan Sewell Biotechnology Co., Ltd.; AST assay kit and ALT assay kit were purchased from Nanjing Jiancheng Bioengineering Institute; TUNEL detection kit (batch number 11684817910) was purchased from Roche, Switzerland; rat Luminex screening detection kit (batch number LXSARM-07) was purchased from R&D Systems, USA. Water was ultrapure water, and the other reagents were of analytical grade.
[0059] 3. Instruments
[0060] XS205DU electronic balance (Mettler Toledo, Switzerland); Synergy H2 full-function microplate reader (BioTek, USA); JJ-12J dehydrator (Wuhan Junjie Electronics Co., Ltd.); JB-P5 paraffin embedding machine (Wuhan Junjie Electronics Co., Ltd.); RM2016 pathology slicer (Shanghai Leica Instrument Co., Ltd.); KD-P tissue slide machine (Zhejiang Jinhua Kedi Instrument Equipment Co., Ltd.); Nikon Ni-U three-person microscope (Nikon, Japan); Nikon EclipseC1 upright fluorescence microscope (Nikon, Japan); Luminex MAGPIXR analyzer (Luminex, USA).
[0061] II. Example 1: Determination of EG dosage in experimental rats
[0062] According to the literature, the median cumulative toxic dose of Polygonum multiflorum in clinical practice is 205g. (Reference: Tu Can, Ge Feilin, Guo Yuming, et al. Clinical characteristics of Polygonum multiflorum-related liver injury and rationality of medication analysis [J]. Chinese Pharmacovigilance, 2019, 16 (5): 270-276.) According to the pharmacological conversion of the dosage of human and experimental rats, the median cumulative toxic dose of Polygonum multiflorum taken by experimental rats is 18.45g / kg (205g×6.3÷70kg). (Among them, the conversion coefficient between human and experimental rat is 6.3, and the weight of an adult is 70kg) Similarly, the EG content in 77 batches of Polygonum multiflorum medicinal materials was consulted and summarized, and it was found that the content of EG in Polygonum multiflorum medicinal materials is not a fixed value, but is in a fluctuation range of 0.41mg / g to 6.04mg / g.(Reference: [1] Li YX, Gong XH, Liu MC, et al. A New Strategy for Quality Evaluation and Identification of Representative Chemical Components in Polygonum multiflorum Thunb. [J]. Evidence-Based Complementray and Alternative Medicine, 2017, 2017: 6238464. [2] Gao D, Li YM, Li CY, et al. Establishment and Validation of Quantitative Analysis of Multi-Components by Single Marker forQuality Control of Polygoni Multiflori Radix[J].Analytical Methods, 2016, 39: 1-27. [3] Li Shuaifeng, Zheng Chuanzhu, Zhang Li, et al. Effects of different harvesting periods on the contents of diphenylethylene glycosides and anthraquinone components in Polygonum multiflorum [J]. Modern Chinese Medicine, 2015, 17(11): 1177-1179. [4] Luo Yiyuan, Liu Juanxiu, Liu Xunhong, et al. Dynamic accumulation analysis of multifunctional substances in Polygonum multiflorum at different harvesting periods [J]. Chinese Journal of Traditional Chinese Medicine, 2015, 40(13): 2565-2570. [5] Yang Yanjing, Lan Caiwu, He Dingxiang, et al. Effect of different processing methods on the quality of Polygonum multiflorum slices [J]. Chinese Journal of Experimental Traditional Chinese Medicine, 2015(15):31-34. [6] Luo Yiyuan, Liu Juanxiu, Liu Xunhong, et al. Study on simultaneous determination of the contents of seven index components in Polygonum multiflorum by micellar electrokinetic capillary electrophoresis [J]. Chinese Journal of Pharmacy, 2015(9):802-807. [7] Luo Dingqiang, Liu Yue, Wang Guohai, et al. Quality analysis of Polygonum multiflorum and processed Polygonum multiflorum [J]. Chinese Medicinal Materials, 2016(10).).
[0063] According to the cumulative toxic dose of experimental rats (18.45g / kg) and the content range of EG in Polygonum multiflorum (0.41mg / g~6.04mg / g), it can be estimated that the dosage of EG in experimental rats is 8mg / kg~112mg / kg (minimum value 18.45g / kg×0.41mg / g, maximum value 18.45g / kg×6.04mg / g). According to the principle of setting multiple doses in pharmacological experiments, the dosage of EG in rats can be set to 8mg / kg, 16mg / kg, 32mg / kg, 64mg / kg, 128mg / kg; considering that the estimated dosage range is relatively wide, the dosage in the actual experiment is set to 16mg / kg, 32mg / kg, 64mg / kg.
[0064] 1. Sample Preparation
[0065] Preparation of rheumatoid artemisia-8-O-glucoside solution: The required amount of rheumatoid artemisia-8-O-glucoside was calculated according to the dosage (16 mg / kg, 32 mg / kg, 64 mg / kg), vortexed and dissolved in 0.5% sodium carboxymethylcellulose solution, and stored at 4°C for later use;
[0066] Preparation of endotoxin (lipopolysaccharide, LPS) solution: The amount of endotoxin required was calculated according to the dosage (2.8 mg / kg), vortexed and dissolved with sterile physiological saline, and stored at 4°C for future use.
[0067] 2. Animal Experiments
[0068] 2.1 Animal grouping: Forty-eight SD rats were randomly divided into 8 groups (n=6): normal control group (Normal), low-dose emodin-8-O-glucoside group (L-EG), medium-dose emodin-8-O-glucoside group (M-EG), high-dose emodin-8-O-glucoside group (H-EG), LPS model group (LPS), LPS combined with low-dose emodin-8-O-glucoside group (LPS / L-EG), LPS combined with medium-dose emodin-8-O-glucoside group (LPS / M-EG), and LPS combined with high-dose emodin-8-O-glucoside group (LPS / H-EG).
[0069] 2.2 Dosing and specimen collection: After fasting for 12 hours, rats were weighed and dosed according to body weight. Among them, EG samples (16 mg / kg body weight, 32 mg / kg body weight, or 64 mg / kg body weight, 1 ml of drug solution volume / 100 g body weight) were administered by gavage (ig.), and LPS (2.8 mg / kg body weight, drug solution volume 0.35 ml / 100 g body weight) was injected into the tail vein (iv.) 3 hours later. 7 hours after LPS tail vein injection, rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg / kg body weight), blood was collected from the inferior vena cava, and liver samples were collected (references for dosing and specimen collection methods: Li Chunyu, Li Xiaofei, Tu Can, et al. Evaluation of Polygonum multiflorum idiosyncratic liver injury based on endotoxin model [J]. Acta Pharmaceutica Sinica, 2015 (1): 28-33.).
[0070] The groups and dosing instructions are as follows:
[0071] Normal group: 0.5% sodium carboxymethylcellulose solution (ig.) + normal saline (iv.);
[0072] LPS group: 0.5% sodium carboxymethylcellulose solution (ig.) + LPS (iv.);
[0073] L-EG group: low-dose EG (ig.) + normal saline (iv.);
[0074] M-EG group: medium-dose EG (ig.) + normal saline (iv.);
[0075] H-EG group: high-dose EG (ig.) + normal saline (iv.);
[0076] LPS / L-EG group: low-dose EG (ig.) + LPS (iv.);
[0077] LPS / M-EG group: medium dose EG (ig.) + LPS (iv.).
[0078] LPS / H-EG group: high-dose EG (ig.) + LPS (iv.).
[0079] 3. Index detection
[0080] Detection of plasma transaminases: The rat blood was collected in vitro, and the plasma was obtained by centrifugation (3000r / min, 10min). The activity of alanine aminotransferase (ALT / GPT) and aspartate aminotransferase (AST / GOT) in the plasma was detected using a kit.
[0081] 3. Results
[0082] 1. Comparison of plasma ALT and AST test results
[0083] ALT and AST are the most widely used biochemical indicators for evaluating liver function or liver damage in clinical practice. Figure 1 It can be seen that compared with the normal control group, the single drug administration groups (L-EG group, M-EG group, H-EG group, LPS group) failed to cause significant changes in the activity of ALT and AST, the plasma biochemical indicators of rats (P>0.05); compared with the LPS model control group, the combined administration of LPS and H-EG could cause significant changes in the liver function indicators ALT and AST of rats (P<0.05), while LPS and L-EG or M-EG failed to significantly change the transaminase level (P>0.05).
[0084] Table 1 Effects of different doses of EG on the activities of plasma ALT and AST in LPS model rats ( n=8)
[0085] Group <![CDATA[Dose (mg·kg -1 )]]> <![CDATA[ALT(U·L -1 )]]> <![CDATA[AST(U·L -1 )]]> Normal - 21.71±3.70 34.37±2.37 L-EG 16 21.02±2.46 34.49±3.66 M-EG 32 19.47±0.96 28.89±8.02 H-EG 64 22.79±0.92 32.87±1.88 LPS 2.8 25.41±1.79 36.11±7.12 LPS / L-EG 2.8+16 26.56±6.76 37.44±2.75 LPS / M-EG 2.8+32 <![CDATA[29.79±6.42 * ]]> 40.90±7.05 LPS / H-EG 2.8+64 <![CDATA[39.45±5.70 **## ]]> <![CDATA[50.39±10.12 **# ]]>
[0086] Note: *P<0.05, **P<0.01vs normal control group (Normal); # P<0.05, ## P<0.01vs model group (LPS)
[0087] This result shows that the high-dose EG sample (64 mg / kg, i.e. H-EG group) combined with LPS will cause a significant increase in the biochemical indicators of liver injury ALT and AST in plasma; EG showed dose-dependent damage in the LPS model, suggesting that EG may be a risk substance for idiosyncratic liver injury in Polygonum multiflorum. The EG used in subsequent experiments was evaluated at this high dose (64 mg / kg).
[0088] Example 2: Objective identification of liver damage caused by TSG combined with EG in experimental rats
[0089] 1. Methods
[0090] 1. Sample Preparation
[0091] Preparation of rheum-8-O-glucoside solution The required amount of rheum-8-O-glucoside was calculated according to the dosage (64 mg / kg), vortexed and dissolved in 0.5% sodium carboxymethylcellulose solution, and stored at 4°C for later use;
[0092] Preparation of trans-stilbene glycoside solution The required amount of trans-stilbene glycoside was calculated according to the dosage (500 mg / kg), vortexed and dissolved with 0.5% sodium carboxymethyl cellulose solution, and stored at 4°C for later use;
[0093] Preparation of mixed solution of trans-stilbene glycoside and rhamnosine-8-O-glucoside The required amount of trans-stilbene glycoside TSG was calculated according to the dosage (500 mg / kg) (reference for the dosage ratio of trans-stilbene glycoside and rhamnosine-8-O-glucoside: Gao Dan, Li Xiaofei, Yin Ping, et al. Preliminary study on the hepatotoxic substance basis of Polygonum multiflorum based on the idea of processing and reducing toxicity [J]. Chinese Herbal Medicine, 2017 (10).), and the required amount of rhamnosine-8-O-glucoside was calculated according to the dosage (64 mg / kg). Different doses of trans-stilbene glycoside were mixed with rhamnosine-8-O-glucoside, and vortexed and dissolved with 0.5% sodium carboxymethyl cellulose solution, and stored at 4°C for later use;
[0094] Preparation of endotoxin (lipopolysaccharide, LPS) solution: The amount of endotoxin required was calculated according to the dosage (2.8 mg / kg), vortexed and dissolved with sterile physiological saline, and stored at 4°C for future use.
[0095] 2. Animal Experiments
[0096] 2.1 Animal grouping: A total of 64 SD rats were randomly divided into 8 groups (n=8), including normal control group (Normal), emodin-8-O-glucoside group (EG), trans-stilbene glycoside group (TSG), a mixture of trans-stilbene glycoside and emodin-8-O-glucoside group (TSG / EG), LPS model group (LPS), LPS combined with emodin-8-O-glucoside group (LPS / EG), LPS combined with trans-stilbene glycoside group (LPS / TSG), and LPS combined with a mixture of trans-stilbene glycoside and emodin-8-O-glucoside group (LPS / TSG / EG).
[0097] 2.2 Dosing and specimen collection: Rats were fasted for 12 hours but not water, then weighed and dosed according to body weight. EG samples and TSG and EG combined samples (dosing solution volume 1 ml / 100 g body weight) were administered by gavage, and LPS (dosing solution volume 0.35 ml / 100 g body weight) was injected into the tail vein 3 hours later. 7 hours after LPS tail vein injection, rats were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg / kg body weight), blood was collected from the inferior vena cava, and liver samples were collected.
[0098] The groups and dosing instructions are as follows:
[0099] Normal group: 0.5% sodium carboxymethylcellulose solution (ig.) + normal saline (iv.);
[0100] LPS group: 0.5% sodium carboxymethylcellulose solution (ig.) + LPS (iv.);
[0101] EG group: EG (ig.) + saline (iv.);
[0102] TSG group: TSG (ig.) + normal saline (iv.);
[0103] TSG / EG group: mixed solution of TSG and EG (ig.) + normal saline (iv.);
[0104] LPS / EG group: EG(ig.)+LPS(iv.);
[0105] LPS / TSG group: TSG(ig.)+LPS(iv.);
[0106] LPS / TSG / EG group: mixed solution of TSG and EG (ig.) + LPS (iv.).
[0107] 3. Index detection
[0108] 3.1 Detection of plasma transaminases: Blood was collected from rats and centrifuged (3000 r / min, 10 min) to obtain plasma. The activity of alanine aminotransferase (ALT / GPT) and aspartate aminotransferase (AST / GOT) in plasma was detected using a kit.
[0109] 3.2 Detection of liver tissue pathology: Rat liver tissue was collected, fixed with universal tissue fixative, routinely sliced, and stained with HE. The pathological changes of liver tissue were observed under an optical microscope and images were collected.
[0110] 3.3 Detection of apoptotic cells in liver tissue
[0111] The rat liver tissues were collected, fixed with 10% neutral formalin, and routine pathological sections were performed. The number of apoptotic hepatocytes was detected using the TUNEL kit.
[0112] 3.4 Detection of inflammatory cytokines
[0113] The levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-10 (IL-10) in plasma were determined by multifactor detection kit and Luminex liquid chip technology according to the kit instructions.
[0114] 4. Statistical Analysis
[0115] SPSS 19.0 software was used for statistical analysis, and the experimental data were The quantitative data were analyzed by one-way analysis of variance (ANOVA), with a significance level of P < 0.05 or P < 0.01.
[0116] 2. Results
[0117] 1. Comparison of plasma ALT and AST test results
[0118] From Table 2 and Figure 2 It can be seen that compared with the normal control group, the single drug administration groups (EG group, TSG group, TSG / EG group, LPS group) failed to cause significant changes in the activity of ALT and AST in rat plasma biochemical indicators (P>0.05); compared with the LPS model control group, the combined administration of LPS and TSG / EG can cause significant changes in rat liver function indicators ALT and AST (P<0.05), and the liver function indicators of the LPS / TSG / EG group increased more significantly than those of the LPS / EG group (P<0.05).
[0119] Table 2 Effects of TSG combined with EG on the activities of plasma ALT and AST in LPS model rats ( n=8)
[0120] Group <![CDATA[Dose (mg·kg -1 )]]> <![CDATA[ALT(U·L -1 )]]> <![CDATA[AST(U·L -1 )]]> Normal - 21.01±2.00 32.95±4.36 TSG 500 19.66±4.33 26.01±6.19 EG 64 21.25±2.04 29.51±5.28 TSG / EG 500+64 22.08±8.10 31.98±7.26 LPS 2.8 27.16±8.19 38.88±7.93 LPS / TSG 2.8+500 29.09±9.29 45.41±7.92 LPS / EG 2.8+64 <![CDATA[45.22±10.84 **## ]]> <![CDATA[62.44±9.12 **## ]]> LPS / TSG / EG 2.8+(500+64) <![CDATA[58.59±13.75 **##^ ]]> <![CDATA[77.43±16.64 **##^ ]]>
[0121] Note: *P<0.05, **P<0.01vs normal control group; # P<0.05, ## P<0.01vs LPS model group; ^P<0.05, ^^P<0.01vs LPS / EG group.
[0122] This result indicates that TSG can aggravate the liver injury effect of EG in LPS model rats.
[0123] 2. Liver Histopathological Analysis
[0124] from Figure 3 It can be seen that the pathological sections of the rat liver tissues in the normal control group, EG group, and TSG / EG group showed that the hepatocytes were uniform in size, clear in structure, and neatly arranged. A small amount of inflammatory cell infiltration was observed in the portal area of the rat liver tissue sections in the model control group and LPS / TSG / EG group, but there were no obvious pathological changes; however, obvious pathological changes were observed in the LPS / EG group and LPS / TSG / EG group, including disordered arrangement of hepatocytes, swelling of some hepatocytes in the central vein, and a large amount of inflammatory cell infiltration in the portal area.
[0125] This result indicates that high doses of EG samples combined with LPS can cause significant changes in rat liver tissue pathology.
[0126] 3. Analysis of Cell Apoptosis in Liver Tissue
[0127] Compared with the normal control group, the apoptosis rates of liver tissue cells in the LPS / EG group and the LPS / TSG / EG group were significantly increased (P < 0.05); while the apoptosis rates of cells in the other groups did not change significantly (P > 0.05). Figure 4 and Table 3. Wherein, cell apoptosis rate % = (number of apoptotic cells / total number of cells)*100%.
[0128] Table 3 Effects of TSG combined with EG on apoptosis of hepatocytes in LPS model rats ( n=8)
[0129] Group <![CDATA[Dose (mg·kg -1 )]]> Apoptosis rate (%) Normal - 0.48±0.11 EG 64 0.42±0.06 TSG 500 0.38±0.04 TSG / EG 500+64 0.39±0.06 LPS 2.8 1.30±0.44 LPS / TSG 2.8+500 1.67±0.57 LPS / EG 2.8+64 <![CDATA[2.72±0.12 **# ]]> LPS / TSG / EG 2.8+(500+64) <![CDATA[3.33±0.06 **#^^ ]]>
[0130] Note: *P<0.05, **P<0.01vs normal control group; # P<0.05, ## P<0.01vs LPS model group; ^P<0.05, ^^P<0.01vs LPS / EG group.
[0131] This result indicates that high-dose EG samples combined with LPS will cause apoptosis of rat liver tissue cells; TSG can increase hepatocyte apoptosis, thereby aggravating the liver damage effect of EG in the LPS model.
[0132] 4. Analysis of inflammatory cytokine content
[0133] LPS can stimulate monocytes / macrophages to secrete a large amount of inflammatory cytokines. Figure 5 As shown in Table 4, compared with the normal control group, the levels of TNF-a, IL-6, IL-1β, IL-10, and IFN-γ in the LPS group were significantly increased (P < 0.05); although trace amounts of LPS can cause an increase in inflammatory cytokines, it did not cause liver damage in rats based on transaminase levels and HE staining results. Similarly, compared with the LPS group, the levels of TNF-a, IL-6, IL-1β, IL-10, and IFN-γ in the LPS / EG group and the LPS / TSG / EG group were significantly increased (P < 0.05), and the levels of inflammatory cytokines in the LPS / TSG / EG group increased more.
[0134] Table 4 Effects of TSG combined with EG on the levels of plasma inflammatory cytokines in LPS model rats ( n=8)
[0135]
[0136]
[0137] Note: *P<0.05, **P<0.01vs normal control group; #P<0.05, ## P<0.01vs LPS model group; ^P<0.05, ^^P<0.01vs LPS / EG group.
[0138] This result indicates that the combination of high-dose EG samples and LPS will cause significant changes in inflammatory cytokines; TSG can increase the changes in inflammatory cytokines, thereby aggravating the liver injury effect of EG in the LPS model.
[0139] Example 3: Control limit of the content of susceptible component EG
[0140] From the screening of the dosage of EG in experimental rats in Example 1, it was concluded that the median of the cumulative toxic dose of Polygonum multiflorum taken by experimental rats was 18.45 g / kg; from the objective identification of EG-induced idiosyncratic liver damage in rats in the immune stress model in Example 2, it was concluded that the safe dosage of EG in rats was ≤32 mg / kg; then the safe limit of the content of the susceptible component EG in Polygonum multiflorum was ≤1.7 mg / g (32 mg / kg÷18.45 g / kg). That is, when the EG content is ≤0.17%, the risk of Polygonum multiflorum-induced liver damage is relatively small.
[0141] Combined with the results of Example 1 on the screening of EG dosage in experimental rats and Example 2 on the objective identification of liver damage caused by TSG combined with EG in experimental rats, it can be seen that EG may be an important susceptible component of Polygonum multiflorum idiosyncratic liver damage, and TSG can aggravate the degree of liver damage caused by EG in the LPS model by promoting hepatocyte apoptosis and increasing the content of inflammatory cytokines. In order to reduce the risk of clinical medication, it is preliminarily suggested that the susceptible component EG content of 0.17% can be used as the quality control limit of the production and processing process of Polygonum multiflorum.
[0142] Although the embodiments disclosed in this application are as above, the contents described are only embodiments adopted to facilitate understanding of this application and are not intended to limit this application. Any technician in the field to which this application belongs can make any modifications and changes in the form and details of implementation without departing from the spirit and scope disclosed in this application, but the scope of patent protection of this application shall still be based on the scope defined in the attached claims.
Claims
1. Use of rhamnosine-8-O-glucoside in the preparation of a drug that does not cause idiosyncratic liver damage, wherein: Based on the total weight of Polygonum multiflorum, the content of rhein-8-O-glucoside is ≤0.17%, and the dosage of rhein-8-O-glucoside is 16 mg / kg-32 mg / kg.
2. The use according to claim 1, wherein The content of rhein-8-O-glucoside is 0.04%-0.17% based on the total weight of Polygonum multiflorum.
